A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Overview of attention for article published in Investigational New Drugs, May 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 3 X users
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 26 Dimensions

Readers on

mendeley: 55 Mendeley

Summary X Facebook Wikipedia Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 30,248 followers.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with https://t.co/5oQa8iOsk2 #hvhebron #onco

Reply Repost Favourite

RT @Aiims1742: A Takeda / Millennium ADC targeting guanyl cyclase C flunks out in #PancreaticCancer https://t.co/wjIW2AyBWz https://t.co/O…

Reply Repost Favourite

A Takeda / Millennium ADC targeting guanyl cyclase C flunks out in #PancreaticCancer https://t.co/wjIW2AyBWz https://t.co/O4nx48QFZB

Reply Repost Favourite